Taylor K. Wirth

Representative Experience

• WaySpring (f/k/a axialHealthcare) Secures $75 Million Investment

  Representation of Wayspring, formerly Axial Healthcare, in its $75 million investment from Valtruis, Centene Corporation, CareSource, HLM Venture Partners and other leading investors. Wayspring will use the capital to scale its value-based care solution, a full-risk medical home model for substance use disorder (SUD).

  We represented Wayspring, formerly Axial Healthcare, in its $75 million investment from Valtruis, Centene Corporation, CareSource, HLM Venture Partners and...
  Read More
• Gladstone Commercial Corporation Completes Public Offering of Series G Preferred Stock

  Representation of Gladstone Commercial Corporation in its offering of 4,000,000 shares of its newly designated 6.00% Series G Cumulative Redeemable Preferred Stock raising $100.0 million in gross proceeds and approximately $96.7 million in net proceeds after payment of underwriting discounts and commissions and estimated expenses of the offering. Stifel, Goldman Sachs & Co. LLC, B. Riley Securities and Baird acted as joint book-running managers of the offering, and Janney Montgomery Scott LLC, Ladenburg Thalmann, Colliers Securities LLC and Wedbush Securities served as co-managers of the offering.

   

  Gladstone Commercial Corporation (Nasdaq: GOOD) is a real estate investment trust focused on acquiring, owning and operating net leased industrial and office properties across the United States.

  We represented Gladstone Commercial Corporation in its offering of 4,000,000 shares of its newly designated 6.00% Series G Cumulative Redeemable...
  Read More
• $265 Million Financing for NN, Inc.

  Representation of NN, Inc. (NASDAQ: NNBR) in a new financing with J.P. Morgan, funds managed by Oaktree Capital Management, L.P., and investment funds managed by Morgan Stanley Tactical Value providing a $50 million asset-based credit line (ABL), a 5.5-year $150 million term loan, and a $65 million preferred stock issuance, respectively. Proceeds from the transaction will be used to repay the current principal balance of $70 million on its term loans due in 2022, to redeem its current $100 million outstanding preferred stock, prior to the increase in redemption premium at March 31, 2021, and pay off its fixed interest rate swap of $14 million. The transaction enables the company to strengthen its balance sheet by extending its capital structure’s maturity at an attractive blended cost of capital, allowing the company financial flexibility to continue its current business transformation efforts.

  We represented NN, Inc. (NASDAQ: NNBR) in a new financing with J.P. Morgan, funds managed by Oaktree Capital Management, L.P., and...
  Read More
  Client Type: Public Company
• Louisiana-Pacific Corporation Completes $350 Million Senior Notes Offering

  Representation of Louisiana-Pacific Corporation in its offering of $350,000,000 of 3.625% senior notes due 2029.

  We represented Louisiana-Pacific Corporation in its offering of $350,000,000 of 3.625% senior notes due 2029. BofA Securities, Goldman Sachs and...
  Read More
  Client Type: Public Company
• Pharos Capital’s Complete Health Partners Acquires Family Care Physicians, LLP

  Representation of Complete Health Partners, a Pharos Capital portfolio company and physician-centric, professionally managed, technology-enabled primary care group, in its acquisition of Family Care Physicians, LLP is a Florida-based medical group practice specializing in family and geriatric medicine.

  We represented Complete Health Partners, a Pharos Capital portfolio company and physician-centric, professionally managed, technology-enabled primary care group, in its...
  Read More
  Client Type: Private Company
• ClearPoint Neuro, Inc. Completes Public Offering of Common Stock

  Representation of ClearPoint Neuro, Inc. in its public offering of 2,127,660 shares with proceeds of $46,800,000.

  We represented ClearPoint Neuro, Inc. in its public offering of 2,127,660 shares with proceeds of $46,800,000. B. Riley Securities acted...
  Read More
  Client Type: Public Company
• ClearPoint Neuro, Inc. Completes Public Offering of Common Stock

  Representation of ClearPoint Neuro, Inc. in its public offering of 2,127,660 shares with proceeds of $46,800,000. B. Riley Securities acted as book-running manager and Lake Street Capital Markets, LLC acted as co-manager for the offering.

   

  We represented ClearPoint Neuro, Inc. in its public offering of 2,127,660 shares with proceeds of $46,800,000. B. Riley Securities acted...
  Read More
  Client Type: Public Company
• Pro Bono Team Helps Form Mosaic Changemakers

  Creation of the corporate structure for Mosaic Changemakers – our team helped the new organization obtain tax exempt nonprofit status and transfer the program to a new entity, and provided advice for formation and business practices

  Our pro bono team worked with Renata Soto, Senior Fellow at the Harvard University Advanced Leadership Initiative and co-founder and...
  Read More
  Client Type: Pro Bono
• Gladstone Land Corporation Completes Public Offering of Series D Preferred Stock

  Representation of Gladstone Land Corporation in its offering of 2,100,000 shares of its newly designated 5.00% Series D Cumulative Term Preferred Stock with proceeds of $58,000,000.

  We represented Gladstone Land Corporation in its offering of 2,100,000 shares of its newly designated 5.00% Series D Cumulative Term...
  Read More
  Client Type: Public Company
• ClearPoint Neuro, Inc. (f/k/a/ MRI Interventions, Inc.) Closes $17.5 Million Strategic Investment from PTC Therapeutics, Inc. and Petrichor Healthcare Capital Management and Announces Additional $7.5 Million Strategic Investment in December 2020.

  We represented ClearPoint Neuro, Inc. (f/k/a MRI Interventions, Inc.), a global therapy-enabling platform company providing navigation and delivery to the brain, in its $17.5 million strategic investment from PTC Therapeutics, Inc. and Petrichor Healthcare Capital Management, with $10.0 million of notes funded by PTC and $7.5 million of notes funded by Petrichor. With the net proceeds from the sale of the notes to PTC and Petrichor, the ClearPoint Neuro intends to repay in full its existing secured indebtedness, and to fund product commercialization, internal research and development, and general corporate requirements. Additionally, we advised ClearPoint Neuro in the draw of $7.5 million additional proceeds from Petrichor in December 2020. ClearPoint Neuro  intends to use net proceeds to continue funding global product commercialization, external strategic portfolio partnerships, and internal research and development efforts.

  We represented ClearPoint Neuro, Inc. (f/k/a MRI Interventions, Inc.), a global therapy-enabling platform company providing navigation and delivery to the...
  Read More
  Client Type: Private Company